These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

226 related items for PubMed ID: 11489797

  • 1. Pan-trk inhibition decreases metastasis and enhances host survival in experimental models as a result of its selective induction of apoptosis of prostate cancer cells.
    Weeraratna AT, Dalrymple SL, Lamb JC, Denmeade SR, Miknyoczki S, Dionne CA, Isaacs JT.
    Clin Cancer Res; 2001 Aug; 7(8):2237-45. PubMed ID: 11489797
    [Abstract] [Full Text] [Related]

  • 2. Sustained in vivo regression of Dunning H rat prostate cancers treated with combinations of androgen ablation and Trk tyrosine kinase inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555).
    George DJ, Dionne CA, Jani J, Angeles T, Murakata C, Lamb J, Isaacs JT.
    Cancer Res; 1999 May 15; 59(10):2395-401. PubMed ID: 10344749
    [Abstract] [Full Text] [Related]

  • 3. Trk receptor inhibition induces apoptosis of proliferating but not quiescent human osteoblasts.
    Pinski J, Weeraratna A, Uzgare AR, Arnold JT, Denmeade SR, Isaacs JT.
    Cancer Res; 2002 Feb 15; 62(4):986-9. PubMed ID: 11861369
    [Abstract] [Full Text] [Related]

  • 4. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B, Singh J, Gingrich D, Angeles T, Albom M, Yang S, Chang H, Robinson C, Hunter K, Dobrzanski P, Jones-Bolin S, Pritchard S, Aimone L, Klein-Szanto A, Herbert JM, Bono F, Schaeffer P, Casellas P, Bourie B, Pili R, Isaacs J, Ator M, Hudkins R, Vaught J, Mallamo J, Dionne C.
    Cancer Res; 2003 Sep 15; 63(18):5978-91. PubMed ID: 14522925
    [Abstract] [Full Text] [Related]

  • 5. The Trk tyrosine kinase inhibitor CEP-701 (KT-5555) exhibits significant antitumor efficacy in preclinical xenograft models of human pancreatic ductal adenocarcinoma.
    Miknyoczki SJ, Chang H, Klein-Szanto A, Dionne CA, Ruggeri BA.
    Clin Cancer Res; 1999 Aug 15; 5(8):2205-12. PubMed ID: 10473107
    [Abstract] [Full Text] [Related]

  • 6. Cell cycle-independent death of prostate adenocarcinoma is induced by the trk tyrosine kinase inhibitor CEP-751 (KT6587).
    Dionne CA, Camoratto AM, Jani JP, Emerson E, Neff N, Vaught JL, Murakata C, Djakiew D, Lamb J, Bova S, George D, Isaacs JT.
    Clin Cancer Res; 1998 Aug 15; 4(8):1887-98. PubMed ID: 9717816
    [Abstract] [Full Text] [Related]

  • 7. Tyrosine kinase inhibitor CEP-701 blocks the NTRK1/NGF receptor and limits the invasive capability of prostate cancer cells in vitro.
    Festuccia C, Muzi P, Gravina GL, Millimaggi D, Speca S, Dolo V, Ricevuto E, Vicentini C, Bologna M.
    Int J Oncol; 2007 Jan 15; 30(1):193-200. PubMed ID: 17143529
    [Abstract] [Full Text] [Related]

  • 8. Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers.
    Xu Y, Dalrymple SL, Becker RE, Denmeade SR, Isaacs JT.
    Clin Cancer Res; 2006 Jul 01; 12(13):4072-9. PubMed ID: 16818707
    [Abstract] [Full Text] [Related]

  • 9. Anti-proliferative effect of the kinase inhibitor K252a on human prostatic carcinoma cell lines.
    Delsite R, Djakiew D.
    J Androl; 1996 Jul 01; 17(5):481-90. PubMed ID: 8957691
    [Abstract] [Full Text] [Related]

  • 10. Rational basis for Trk inhibition therapy for prostate cancer.
    Weeraratna AT, Arnold JT, George DJ, DeMarzo A, Isaacs JT.
    Prostate; 2000 Oct 01; 45(2):140-8. PubMed ID: 11027413
    [Abstract] [Full Text] [Related]

  • 11. An orally active Amazonian plant extract (BIRM) inhibits prostate cancer growth and metastasis.
    Dandekar DS, Lokeshwar VB, Cevallos-Arellano E, Soloway MS, Lokeshwar BL.
    Cancer Chemother Pharmacol; 2003 Jul 01; 52(1):59-66. PubMed ID: 12734674
    [Abstract] [Full Text] [Related]

  • 12. A potent indole-3-carbinol derived antitumor agent with pleiotropic effects on multiple signaling pathways in prostate cancer cells.
    Weng JR, Tsai CH, Kulp SK, Wang D, Lin CH, Yang HC, Ma Y, Sargeant A, Chiu CF, Tsai MH, Chen CS.
    Cancer Res; 2007 Aug 15; 67(16):7815-24. PubMed ID: 17699787
    [Abstract] [Full Text] [Related]

  • 13. Anti-vascular endothelial growth factor receptor 2 antibody reduces tumorigenicity and metastasis in orthotopic prostate cancer xenografts via induction of endothelial cell apoptosis and reduction of endothelial cell matrix metalloproteinase type 9 production.
    Sweeney P, Karashima T, Kim SJ, Kedar D, Mian B, Huang S, Baker C, Fan Z, Hicklin DJ, Pettaway CA, Dinney CP.
    Clin Cancer Res; 2002 Aug 15; 8(8):2714-24. PubMed ID: 12171905
    [Abstract] [Full Text] [Related]

  • 14. Antitumor activity of CEP-751 (KT-6587) on human neuroblastoma and medulloblastoma xenografts.
    Evans AE, Kisselbach KD, Yamashiro DJ, Ikegaki N, Camoratto AM, Dionne CA, Brodeur GM.
    Clin Cancer Res; 1999 Nov 15; 5(11):3594-602. PubMed ID: 10589776
    [Abstract] [Full Text] [Related]

  • 15. Effect of CEP-751 (KT-6587) on neuroblastoma xenografts expressing TrkB.
    Evans AE, Kisselbach KD, Liu X, Eggert A, Ikegaki N, Camoratto AM, Dionne C, Brodeur GM.
    Med Pediatr Oncol; 2001 Jan 15; 36(1):181-4. PubMed ID: 11464878
    [Abstract] [Full Text] [Related]

  • 16. Simultaneous blockade of platelet-derived growth factor-receptor and epidermal growth factor-receptor signaling and systemic administration of paclitaxel as therapy for human prostate cancer metastasis in bone of nude mice.
    Kim SJ, Uehara H, Yazici S, Langley RR, He J, Tsan R, Fan D, Killion JJ, Fidler IJ.
    Cancer Res; 2004 Jun 15; 64(12):4201-8. PubMed ID: 15205332
    [Abstract] [Full Text] [Related]

  • 17. Clioquinol, a therapeutic agent for Alzheimer's disease, has proteasome-inhibitory, androgen receptor-suppressing, apoptosis-inducing, and antitumor activities in human prostate cancer cells and xenografts.
    Chen D, Cui QC, Yang H, Barrea RA, Sarkar FH, Sheng S, Yan B, Reddy GP, Dou QP.
    Cancer Res; 2007 Feb 15; 67(4):1636-44. PubMed ID: 17308104
    [Abstract] [Full Text] [Related]

  • 18. The neurotrophin-trk receptor axes are critical for the growth and progression of human prostatic carcinoma and pancreatic ductal adenocarcinoma xenografts in nude mice.
    Miknyoczki SJ, Wan W, Chang H, Dobrzanski P, Ruggeri BA, Dionne CA, Buchkovich K.
    Clin Cancer Res; 2002 Jun 15; 8(6):1924-31. PubMed ID: 12060637
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. A molecular mimic of phosphorylated prolactin markedly reduced tumor incidence and size when DU145 human prostate cancer cells were grown in nude mice.
    Xu X, Kreye E, Kuo CB, Walker AM.
    Cancer Res; 2001 Aug 15; 61(16):6098-104. PubMed ID: 11507059
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.